Literature DB >> 29097016

Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods.

Wenli Cai1, Seth M Steinberg2, Miriam A Bredella3, Gina Basinsky1, Bhanusupriya Somarouthu1, Scott R Plotkin4, Jeffrey Solomon5, Brigitte C Widemann6, Gordon J Harris1, Eva Dombi7.   

Abstract

OBJECTIVES: Plexiform neurofibromas (PNs) are complex, histologically benign peripheral nerve sheath tumors that are challenging to measure by simple line measurements. Computer-aided volumetric segmentation of PN has become the recommended method to assess response in clinical trials directed at PN. Different methods for volumetric analysis of PN have been developed. The goal of this study is to test the level of agreement in volume measurements and in interval changes using two separate methods of volumetric magnetic resonance imaging analysis.
METHODS: Three independent volume measurements were performed on 15 PN imaged at three time-points using 3DQI software at Massachusetts General Hospital (MGH) and National Cancer Institute (NCI) and MEDx software at NCI.
RESULTS: Median volume differences at each time-point comparing MGH-3DQI and NCI-3DQI were -0.5, -4.2, and -19.9 mL; comparing NCI-3DQI and NCI-MEDx were -21.0, -47.0, and -21.0 mL; comparing MGH-3DQI and NCI-MEDx were -10.0, -70.3, and -29.9 mL. Median differences in percentage change over time comparing MGH-3DQI and NCI-3DQI were -1.7, 1.1, and -1.0%; comparing NCI-3DQI and NCI-MEDx were -2.3, 3.3, and -1.1%; comparing MGH-3DQI and NCI-MEDx were -0.4, 2.0, and -1.5%. Volume differences were <20% of the mean of the two measurements in 117 of 135 comparisons (86.7%). Difference in interval change was <20% in 120 of the 135 comparisons (88.9%), while disease status classification was concordant in 115 of 135 comparisons (85.2%).
CONCLUSIONS: The volumes, interval changes, and progression status classifications were in good agreement. The comparison of two volumetric analysis methods suggests no systematic differences in tumor assessment. A prospective comparison of the two methods is planned. Published by Elsevier Inc.

Entities:  

Keywords:  Neurofibromatosis type 1; plexiform neurofibroma; tumor response evaluation; volumetric MRI

Mesh:

Year:  2017        PMID: 29097016      PMCID: PMC5794522          DOI: 10.1016/j.acra.2017.09.004

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  20 in total

1.  CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.

Authors:  Mizuki Nishino; Mengye Guo; David M Jackman; Pamela J DiPiro; Jeffrey T Yap; Tak K Ho; Hiroto Hatabu; Pasi A Jänne; Annick D Van den Abbeele; Bruce E Johnson
Journal:  Acad Radiol       Date:  2010-10-30       Impact factor: 3.173

2.  Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.

Authors:  Brian Weiss; Brigitte C Widemann; Pamela Wolters; Eva Dombi; Alexander A Vinks; Alan Cantor; Bruce Korf; John Perentesis; David H Gutmann; Elizabeth Schorry; Roger Packer; Michael J Fisher
Journal:  Pediatr Blood Cancer       Date:  2014-06       Impact factor: 3.167

3.  Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Authors:  Brigitte C Widemann; Eva Dombi; Andrea Gillespie; Pamela L Wolters; Jean Belasco; Stewart Goldman; Bruce R Korf; Jeffrey Solomon; Staci Martin; Wanda Salzer; Elizabeth Fox; Nicholas Patronas; Mark W Kieran; John P Perentesis; Alyssa Reddy; John J Wright; AeRang Kim; Seth M Steinberg; Frank M Balis
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

4.  Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

Authors:  Brian Weiss; Brigitte C Widemann; Pamela Wolters; Eva Dombi; Alexander Vinks; Alan Cantor; John Perentesis; Elizabeth Schorry; Nicole Ullrich; David H Gutmann; James Tonsgard; David Viskochil; Bruce Korf; Roger J Packer; Michael J Fisher
Journal:  Neuro Oncol       Date:  2014-10-14       Impact factor: 12.300

5.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Authors:  Eva Dombi; Andrea Baldwin; Leigh J Marcus; Michael J Fisher; Brian Weiss; AeRang Kim; Patricia Whitcomb; Staci Martin; Lindsey E Aschbacher-Smith; Tilat A Rizvi; Jianqiang Wu; Rachel Ershler; Pamela Wolters; Janet Therrien; John Glod; Jean B Belasco; Elizabeth Schorry; Alessandra Brofferio; Amy J Starosta; Andrea Gillespie; Austin L Doyle; Nancy Ratner; Brigitte C Widemann
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

6.  Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

Authors:  Kent A Robertson; Grzegorz Nalepa; Feng-Chun Yang; Daniel C Bowers; Chang Y Ho; Gary D Hutchins; James M Croop; Terry A Vik; Scott C Denne; Luis F Parada; Cynthia M Hingtgen; Laurence E Walsh; Menggang Yu; Kamnesh R Pradhan; Mary K Edwards-Brown; Mervyn D Cohen; James W Fletcher; Jeffrey B Travers; Karl W Staser; Melissa W Lee; Marcie R Sherman; Cynthia J Davis; Lucy C Miller; David A Ingram; D Wade Clapp
Journal:  Lancet Oncol       Date:  2012-10-23       Impact factor: 41.316

7.  Lessons learned from independent central review.

Authors:  R Ford; L Schwartz; J Dancey; L E Dodd; E A Eisenhauer; S Gwyther; L Rubinstein; D Sargent; L Shankar; P Therasse; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

8.  Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images.

Authors:  Wenli Cai; Ara Kassarjian; Miriam A Bredella; Gordon J Harris; Hiroyuki Yoshida; Victor F Mautner; Ralph Wenzel; Scott R Plotkin
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

9.  Recommendations for imaging tumor response in neurofibromatosis clinical trials.

Authors:  Eva Dombi; Simone L Ardern-Holmes; Dusica Babovic-Vuksanovic; Fred G Barker; Steve Connor; D Gareth Evans; Michael J Fisher; Stephane Goutagny; Gordon J Harris; Diego Jaramillo; Matthias A Karajannis; Bruce R Korf; Victor Mautner; Scott R Plotkin; Tina Y Poussaint; Kent Robertson; Chie-Schin Shih; Brigitte C Widemann
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

Review 10.  Achieving consensus for clinical trials: the REiNS International Collaboration.

Authors:  Scott R Plotkin; Jaishri O Blakeley; Eva Dombi; Michael J Fisher; C Oliver Hanemann; Karin S Walsh; Pamela L Wolters; Brigitte C Widemann
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

View more
  6 in total

Review 1.  Current status of MEK inhibitors in the treatment of plexiform neurofibromas.

Authors:  Andrea M Gross; Eva Dombi; Brigitte C Widemann
Journal:  Childs Nerv Syst       Date:  2020-06-30       Impact factor: 1.475

Review 2.  Whole body imaging in musculoskeletal oncology: when, why, and how.

Authors:  Joao R T Vicentini; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2022-07-09       Impact factor: 2.199

3.  MRI based volumetric measurements of vestibular schwannomas in patients with neurofibromatosis type 2: comparison of three different software tools.

Authors:  Philipp Kollmann; Victor-Felix Mautner; Johannes Koeppen; Ralph Wenzel; Jan M Friedman; Johannes Salamon; Said Farschtschi
Journal:  Sci Rep       Date:  2020-07-14       Impact factor: 4.379

Review 4.  Efficacy and Safety of Trametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibroma and Low-Grade Glioma: A Systematic Review and Meta-Analysis.

Authors:  Dun Wang; Lingling Ge; Zizhen Guo; Yuehua Li; Beiyao Zhu; Wei Wang; Chengjiang Wei; Qingfeng Li; Zhichao Wang
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-31

5.  DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.

Authors:  Jian-Wei Zhang; Wei Chen; K Ina Ly; Xubin Zhang; Fan Yan; Justin Jordan; Gordon Harris; Scott Plotkin; Pengyi Hao; Wenli Cai
Journal:  IEEE J Biomed Health Inform       Date:  2022-02-04       Impact factor: 5.772

Review 6.  Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.

Authors:  Robert Galvin; Adrienne L Watson; David A Largaespada; Nancy Ratner; Sara Osum; Christopher L Moertel
Journal:  Curr Oncol Rep       Date:  2021-03-15       Impact factor: 5.075

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.